You are here: Home: Audio Program Guide: BCU 2 | 2007 Audio: BCU 2 | 2007
 
  Go to interview with Frankie Ann Holmes, MD
Go to interview with Eleftherios P Mamounas, MD, MPH
Go to interview with Andrew D Seidman, MD
Go to interview with Allan Lipton, MD
Go to interview with Robert E Marx, DDS
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Holmes, MD Interview with Frankie Ann Holmes, MD
Co-Director, Breast Oncology Research
Texas Oncology and US Oncology Breast Cancer Research
Houston, Texas

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 US Oncology trial 02-103: Feasibility of core needle biopsies in clinical trials to correlate gene signatures with pathologic complete response
Track 3 Potential problems with tumor acquisition and analysis
Track 4 Neoadjuvant chemotherapy and lapatinib, trastuzumab or the combination for patients with HER2-positive disease
Track 5 Degree of HER2 amplification and dose response to trastuzumab
Track 6 Use of anthracycline-containing chemotherapy and trastuzumab in the treatment of HER2-positive disease

Track 7 Patients’ response to requests for multiple biopsies
Track 8 NSABP-B-40: Neoadjuvant docetaxel, alone or with capecitabine or gemcitabine with or without bevacizumab
Track 9 Second interim report of the BCIRG 006 adjuvant trastuzumab trial
Track 10 BCIRG 006: Updated results of topoisomerase II as a predictive factor
Track 11 BCIRG 006 second interim analysis: Efficacy of ACarrowTH versus TCH
Track 12 US Oncology adjuvant trial comparing AC to docetaxel/cyclophosphamide (TC)
Track 13 Use of adjuvant chemotherapy in clinical practice
Track 14 Tolerability of adjuvant AC compared to TC
Track 15 US Oncology clinical trials for patients with HER2-negative or HER2-positive disease
Track 16 Management of cardiac health in patients with breast cancer
Track 17 Dose-dense nanoparticle albumin-bound (nab) paclitaxel and bevacizumab
Track 18 Mechanism of action of nab paclitaxel
Track 19 Potential advantages of nab versus standard paclitaxel
Track 20 Epigenetics and breast cancer
     
Mamounas, MD Eleftherios P Mamounas, MD, MPH
Associate Professor of Surgery
Northeastern Ohio Universities College of Medicine
Medical Director, Aultman Cancer Center
Canton, Ohio

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 NSABP-B-33: Adjuvant exemestane in postmenopausal women completing at least five years of tamoxifen
Track 3 NSABP-B-33: Side effects and tolerability of extended adjuvant exemestane
Track 4 Annualized rate of cancer recurrence among patients with hormone receptor-positive disease
Track 5 Interchangeability of the aromatase inhibitors
Track 6 NSABP-B-42: Duration of adjuvant aromatase inhibitors after five years of hormonal therapy

Track 7 NSABP-B-34: Adjuvant clodronate in patients receiving systemic chemotherapy and/or tamoxifen or no therapy
Track 8 NSABP-B-40: Neoadjuvant docetaxel, alone or with capecitabine or gemcitabine with or without bevacizumab
Track 9 NSABP-B-40 correlative science studies
Track 10 Neoadjuvant clinical trial of bevacizumab with doxorubicin and docetaxel
Track 11 Proposed NSABP neoadjuvant trial of ACarrowpaclitaxel with lapatinib, trastuzumab or the combination followed by adjuvant trastuzumab
Track 12 Role of anthracyclines in the treatment of patients with HER2-positive disease
Track 13 NSABP-B-37: Adjuvant chemotherapy for surgically resected locoregional relapse
     
Andrew D Seidman, MD
Attending Physician
Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, New York

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Phase II trial of weekly versus every two-week versus every three-week nab paclitaxel in combination with bevacizumab as first-line therapy
Track 3 Reversibility of neurotoxicity associated with nab paclitaxel
Track 4 Potential advantages in the administration of nab versus standard paclitaxel
Track 5 Data required to incorporate novel agents into clinical practice
Track 6 Incorporation of bevacizumab into clinical practice

Track 7 Rationale for the use of bevacizumab in the adjuvant setting
Track 8 TAnDEM trial: Trastuzumab with anastrozole in hormone-dependent, HER2-positive metastatic breast cancer
Track 9 Cardiac safety with dose-dense AC followed by paclitaxel/trastuzumab
Track 10 Use of dose-dense AC without paclitaxel
Track 11 US Oncology adjuvant trial comparing AC to docetaxel with cyclophosphamide
Track 12 Perspective on anthracycline- and trastuzumab-associated cardiotoxicity
Track 13 Decreased incidence of breast cancer in the United States
Track 14 EFECT: Fulvestrant versus exemestane following nonsteroidal aromatase inhibitor therapy in advanced breast cancer
Track 15 NSABP-B-33: Extended adjuvant exemestane after five years of tamoxifen
Track 16 Impact of aromatase inhibitor-associated arthralgias
Track 17 Duration of adjuvant hormonal therapy
Track 18 Treatment after completion of up-front adjuvant aromatase inhibitor therapy
     
Lipton, MD Allan Lipton, MD
Professor of Medicine and Oncology
Division of Hematology/Oncology
MS Hershey Medical Center
The Pennsylvania State University
Hershey, Pennsylvania

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Historical development of the bisphosphonates
Track 3 Skeletal-related events in cancer
Track 4 Development of newer, more potent bisphosphonates
Track 5 Impact of bisphosphonates on the management of metastatic bone disease
Track 6 Tolerability and side effects of bisphosphonates

Track 7 Potential mechanisms for the development of osteonecrosis of the jaw (ONJ)
Track 8 Clinical presentation and management of ONJ
Track 9 Overview of adjuvant bisphosphonate data and ongoing trials
Track 10 Denosumab, an antibody against the RANK ligand, for the treatment and prevention of bone metastases
Track 11 Side effects and toxicity of denosumab
Track 12 Future development of denosumab
Track 13 Development of novel agents for the prevention and treatment of bone metastases
Track 14 Importance of understanding bone biology in medical oncology
Track 15 Bone loss associated with adjuvant aromatase inhibitor therapy
Track 16 Monitoring bone health and selecting adjuvant aromatase inhibitor therapy versus tamoxifen

     
Marx, MD Robert E Marx, DDS
Professor of Surgery and Chief
Division of Oral and Maxillofacial Surgery
University of Miami Miller School of Medicine
Miami, Florida
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 History of identification of bisphosphonate-associated ONJ
Track 3 Pathophysiology of bisphosphonate-associated ONJ
Track 4 Clinical presentation of ONJ and treatment of associated infections
Track 5 Differential diagnosis of ONJ
Track 6 Clinical course of ONJ

Track 7 Incidence of bisphosphonate-induced ONJ
Track 8 Determining risks and benefits of bisphosphonates for patients with metastatic breast cancer
Track 9 Prophylactic dental care in patients considered for bisphosphonate therapy
Track 10 Duration of bisphosphonate therapy
Track 11 Bisphosphonate dose accumulation and the risk of developing ONJ
Track 12 Dental implants and bisphosphonate therapy
Track 13 Collaboration between medical oncologists, dentists and oral and maxillofacial surgeons in patient care